Drugs / RBD1016
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05017116 | Aug 2021 → Oct 2023 | chronic hepatitis B virus infection | Suzhou Ribo Life Science Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04685564 | Feb → Sep 2021 | — | Suzhou Ribo Life Science Co. Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06649266 | Aug 2024 → Sep 2026 expected | hepatitis D virus infection | Ribocure Pharmaceuticals AB | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05961098 | Oct 2023 → Apr 2025 | chronic hepatitis B virus infection | Suzhou Ribo Life Science Co. Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RBD1016 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05017116 ↗ |
| Route | Subcutaneous | “single subcutaneous injection of RBD1016” NCT04685564 ↗ |